Next week, Washington D.C. plays host to Neuroscience 2023, SfN. Axol Bioscience will be there presenting a key new poster written in partnership with Sumitomo Pharma America, Inc.

Abstract

Neurodegenerative diseases (NDDs) such as Alzheimer’s Disease and Parkinson’s Disease are a leading cause of physical and cognitive disability, affecting around 15% of the global population [1]. With rising prevalence due to an aging population, there is a growing need for better, safer therapies and curative treatments. The cortex is a key area affected by NDD and is also a common site of drug-induced neurotoxicity (a leading cause of drug attrition), hence it is a major target for drug discovery [2]. However, the lack of physiologically relevant cortical models is a major challenge, with traditional animal models failing to translate from “bench to clinic” and low complexity afforded by simple cell culture and cell line models.

In partnership with Sumitomo Pharma America, Inc., Axol Bioscience performed a blinded study testing eight reference compounds on an isogenic cortical tri-culture axoModel, using an Axion multi-electrode array (MEA) system to measure electrophysiological response. Here we demonstrate robust identification of reference compound mode of actions, validating this axoModel for use in human-relevant drug discovery and neurotoxicity screening.

• Download poster here: Poster: Validation of tri-culture axoModel: a blinded study (axolbio.com)
• Neuroscience 2023 Virtual login: https://cattendee.abstractsonline.com/meeting/10892